메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한요로생식기감염학회 Urogenital Tract Infection Urogenital Tract Infection 제6권 제1호
발행연도
2011.1
수록면
32 - 41 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Multi-drug-resistant Enterobacteriaceae that produce extended-spectrum β-lactamases (ESBLs) have emerged in the communities and hospitals. Because β-lactamases are bacterial enzymes that hydrolyze β-lactamring in antibiotics, cephalosporins are not usually effective. Most ESBLs can be divided into three groups: TEM, SHV, and CTX-M. Recently, AmpC β-lactamase is included in this category. The clinical significance of ESBL bacteria is well known. Initially, ESBL bacteria exhibitmulti-drug resistance, such as co-trimoxazole, tetracycline, gentamicin, and fluroquinolone, as well as broad-spectrum cephalosporins. In addition, they can be transmitted to other places andother people. Moreover, inappropriate empirical therapy to urinary tract infection secondary to ESBL bacteria is usually associated with higher mortality. For these reasons, gram-negative pathogens that produce ESBLs remain an important cause oftherapy failure with newly developed cephalosporins, and incur serious complications and have consequences in infection control in the community. Consequently, it is an urgent issue to understand the characteristics of ESBL bacteria to minimize their spread and to treat ESBL associated urinary tract infection. We herein review the clinical significances of ESBL bacteria in urinary tract infection.

목차

등록된 정보가 없습니다.

참고문헌 (24)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0